Fast Tracked Reviews Consumer Reports Fast Tracked improves the sponsor-FDA dialogue by creating formal opportunities for feedback at critical development milestones; for example, Fast Tracked sponsors are encouraged to hold pre-IND or End of Phase meetings where the FDA can advise on endpoints, comparators, statistical analyses, and biomarker validation, and these interactions under Fast Tracked help ensure that pivotal trials collect the data the FDA will need for approval. Fast Tracked also provides a clearer path to other expedited programs; when the data show substantial evidence of benefit, a Fast Tracked product may be considered for Priority Review, which shortens the FDA’s review goal from ten months to six months, or for Accelerated Approval when surrogate endpoints can reasonably predict clinical benefit, and Fast Tracked serves as a gateway that increases the likelihood a program can progress into these related pathways. For patients and advocacy groups, Fast Tracked means a visible regulatory focus on diseases where treatments are lacking, and the designation often stimulates increased clinical trial enrollment and attention from research funders; Fast Tracked can thus mobilize resources and attention around a promising therapy. At the same time, Fast Tracked is not a guarantee of approval nor does it loosen standards; the FDA retains full authority to require confirmatory trials, to seek additional safety data, and to revoke Fast Tracked if emerging evidence undermines the initial rationale, so the benefit of speed is balanced by ongoing regulatory oversight in the Fast Tracked process.
Fast Tracked Reviews Consumer Reports Fast Tracked is intended for a specific audience and understanding who should pursue Fast Tracked clarifies why it is not a one-size-fits-all approach; Fast Tracked is aimed primarily at drug developers—pharmaceutical and biotechnology companies—who are working on therapies for serious or life-threatening conditions for which existing treatments are inadequate or absent, and Fast Tracked is especially relevant when a program can reasonably claim potential to address an unmet medical need. Fast Tracked is not suitable for drugs intended for non-serious conditions or for products that do not show potential to address unmet needs, so sponsors of lifestyle or minor ailment therapies will typically not pursue Fast Tracked; in those cases, other regulatory pathways are more appropriate. In short, Fast Tracked is for sponsors tackling high-need therapeutic areas where the clinical benefit could be substantial and where early regulatory alignment will materially accelerate development and review. Order Now Fast Tracked Pros & Cons